This article is more than 5 years old. Information may no longer be current.

Cambridge Antibody Technology licenses potential allergic conjunctivitis drug to iCo Therapeutics

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

CAMBRIDGE, England — Cambridge Antibody Technology has granted iCo Therapeutics an exclusive worldwide license to develop and commercialize CAT-213, a human monoclonal antibody developed by CAT as a potential treatment for allergy disorders including allergic conjunctivitis, the companies announced in a press release.

Under the terms of the agreement, iCo Therapeutics will pay CAT an up-front fee, milestone payments for key clinical and regulatory achievements and royalties on future sales. ICo Therapeutics, which will have sole responsibility for all future clinical development and commercialization, plans to initially advance the compound for treating ocular allergies.

CAT-213 is a human anti-eotaxin-1 monoclonal antibody, which has been safe and well-tolerated in phase 1 and 2 studies.